Prognostic signature construction and immunotherapy response analysis for Uterine Corpus Endometrial Carcinoma based on cuproptosis-related lncRNAs DOI
Xu Zhang, Zhiqiang Ye,

Guohong Xiao

et al.

Computers in Biology and Medicine, Journal Year: 2023, Volume and Issue: 159, P. 106905 - 106905

Published: April 11, 2023

Language: Английский

A novel machine learning-based immune prognostic signature for improving clinical outcomes and guiding therapy in colorectal cancer: an integrated bioinformatics and experimental study DOI Creative Commons

Yuanchun Zhao,

Dexu Xun,

Jiajia Chen

et al.

BMC Cancer, Journal Year: 2025, Volume and Issue: 25(1)

Published: Jan. 10, 2025

Immune cells are pivotal components in the tumor microenvironment (TME), which can interact with and significantly influence cancer progression therapeutic outcomes. Therefore, classifying patients based on status of immune within TME is increasingly recognized as an effective approach to identify prognostic biomarkers, paving way for more personalized treatments. Considering high incidence mortality colorectal (CRC), this study, integrated machine learning survival framework incorporating 93 different algorithmic combinations was utilized determine optimal strategy developing immune-related signature (IRPS) average C-index across four CRC cohorts. Notably, IRPS demonstrated be independent risk factor predicting outcomes patients, showing superior performance compared traditional clinical features 63 published signatures both training validation Furthermore, classified low-risk group according showed higher sensitivity immunotherapy than those high-risk group, suggesting that likely benefit from immunotherapy. Through silico screening potential compounds, dasatinib, vinblastine, YM-155 were identified agents patients. In vitro studies knockdown APCDD1, a key component IRPS, inhibited proliferation, migration invasion HT-29 promoted their apoptosis. Thus, serve powerful tool patient prognosis, response candidate drugs, thereby enhancing decision-making treatment evaluation CRC.

Language: Английский

Citations

0
Comprehensive Breslow thickness (BT)-based analysis to identify biological mechanisms associated with melanoma pathogenesis DOI
Yuanjie Liu, Qing Liu, Jiaqi Li

et al.

International Immunopharmacology, Journal Year: 2025, Volume and Issue: 147, P. 114065 - 114065

Published: Jan. 13, 2025

Language: Английский

Citations

0
Impact of cuproptosis in gliomas pathogenesis with targeting options DOI

Mariam Markouli,

Panagiotis Skouras, Christina Piperi

et al.

Chemico-Biological Interactions, Journal Year: 2025, Volume and Issue: unknown, P. 111394 - 111394

Published: Jan. 1, 2025

Language: Английский

Citations

0
Integrated Analysis of Cuproptosis Regulators Reveals Prognostic Significance and Therapeutic Targets in IDH1 Mutant Glioma DOI Creative Commons

Yuxuan Luan,

Yong Meng,

Chunming Sun

et al.

MedComm – Future Medicine, Journal Year: 2025, Volume and Issue: 4(1)

Published: March 1, 2025

ABSTRACT Glioma, characterized by significant heterogeneity and aggressiveness, poses a formidable therapeutic challenge. Cuproptosis, newly identified form of regulated cell death driven copper imbalance, has recently emerged as pivotal factor in tumor biology. However, its role IDH1‐mutant gliomas remains poorly understood. Through comprehensive bioinformatics analysis publicly available datasets, we two distinct subtypes based on cuproptosis regulator expression profiles. Subtype G1 exhibited elevated PD‐L1 expression, increased pro‐tumor immune infiltration, worse clinical outcomes, whereas subtype G2 was enriched antitumor cells associated with improved prognosis. We FDX1 SLC31A1 critical prognostic markers, their upregulation linked to expression. Mechanistically, delineated ceRNA regulatory axis involving COX10‐AS1/miR‐1‐3p/FDX1 that drives glioma progression. Building these insights, developed risk model integrating demonstrating robust predictive accuracy for patient outcomes potential utility guiding individualized treatment strategies. These findings advance our understanding the molecular landscape underscore regulators novel targets biomarkers precision oncology.

Language: Английский

Citations

0
Recent developments in cuproptosis of glioblastoma DOI Creative Commons
Yanhui Chen, Jingxian Zhang, Hongwu Xu

et al.

Pathology - Research and Practice, Journal Year: 2025, Volume and Issue: unknown, P. 155939 - 155939

Published: March 1, 2025

Glioblastoma (GBM) is the most malignant tumor within central nervous system, attributed to its high-grade malignancy, propensity for recurrence, refractoriness conventional therapeutic modalities, and suboptimal efficacy of current targeted therapies. Hence, there an urgent need identify more efficacious molecular targets intervention GBM. The regulated cell death (RCD) has specific signaling factors pathways. targeting RCD considered be one effective therapies At present, cuproptosis a novel form RCD, characterized by distinct mechanism that differentiates it from apoptosis, pyroptosis, necroptosis, ferroptosis. It principal mechanisms, which include copper dependency, accumulation acylated proteins, reduction Fe-S cluster-containing proteins. These processes collectively induce proteotoxic stress, culminating in death. In previous studies, copper-ionized formulations have demonstrated cytotoxic effects on gliomas. Thus, key may able serve as new target GBM treatment. This review delves into several pivotal aspects, including discovery cuproptosis, impact homeostasis tumorigenesis, role GBM, potential therapy this article could reveal strategies

Language: Английский

Citations

0
Establishment and evaluation cuproptosis-related gene signature for predicting the prognosis and immunotherapy response of hepatocellular carcinoma DOI Creative Commons
Shuo Wang,

Xinzi Xue,

Hongyan Bai

et al.

Cancer Cell International, Journal Year: 2025, Volume and Issue: 25(1)

Published: April 28, 2025

Language: Английский

Citations

0
Glioblastoma-associated macrophages in glioblastoma: from their function and mechanism to therapeutic advances DOI
Yuqin Zhang,

Hanxing He,

Xin Fu

et al.

Cancer Gene Therapy, Journal Year: 2025, Volume and Issue: unknown

Published: April 30, 2025

Language: Английский

Citations

0
Molecular Characterization of Cuproptosis-related lncRNAs: Defining Molecular Subtypes and a Prognostic Signature of Ovarian Cancer DOI
Nan Li, Kai Yu, Delun Huang

et al.

Biological Trace Element Research, Journal Year: 2023, Volume and Issue: 202(4), P. 1428 - 1445

Published: Aug. 2, 2023

Language: Английский

Citations

10
Machine learning- and WGCNA-mediated double analysis based on genes associated with disulfidptosis, cuproptosis and ferroptosis for the construction and validation of the prognostic model for breast cancer DOI

Lijun Xu,

Shanshan Wang, Dan Zhang

et al.

Journal of Cancer Research and Clinical Oncology, Journal Year: 2023, Volume and Issue: 149(18), P. 16511 - 16523

Published: Sept. 15, 2023

Language: Английский

Citations

10
The role of ANXA1 in the tumor microenvironment DOI
Lanxin Li, Baiqi Wang,

Shuang Zhao

et al.

International Immunopharmacology, Journal Year: 2024, Volume and Issue: 131, P. 111854 - 111854

Published: March 12, 2024

Language: Английский

Citations

3